Welcome to the Newsroom

NEW YORK & SAN FRANCISCO, Mar 03, 2010 (BUSINESS WIRE) -- Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer's disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or ...

SAN FRANCISCO, March 1, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences: The Cowen Healthcare Conference, Monday, March 8, at 4:45 p.m. Eastern Time at the Marriott Copley Place Hotel in BostonThe ROT...

SAN FRANCISCO, January 12 /PRNewswire/ -- Medivation, Inc. today announced treatment of the first European patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. The trial, known as AFFIRM, will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who ...

SAN FRANCISCO, Dec 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. today announced changes to its organizational structure to support anticipated growth as the company prepares to transition from a development stage company to a commercial organization. As part of this transition, chief financial officer (CFO) Patrick Ma...

SAN FRANCISCO, Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN)today reported on its corporate progress and financial results for the third quarter ended September 30, 2009. "With the signing of our agreement for MDV3100 with Astellas last week, we now have a first-class partner with a global reach, le...

SAN FRANCISCO, Oct 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2009 financial results and provide a general business update on Wednesday, November 4, 2009, at 4:30 p.m. Eastern Time. A press release ...

SAN FRANCISCO, Oct 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Tuesday, October 27, to discuss partnering plans for MDV3100, Medivation's investigational drug which is currently in Phase 3 testing for the treatment o...

SAN FRANCISCO, Sept 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men wit...

SAN FRANCISCO, Aug 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the second quarter ended June 30, 2009. "In the past several months, we completed enrollment in our confirmatory, pivotal Phase 3 CONNECTION trial of dimebon (latrepirdine*...

SAN FRANCISCO, July 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2009 financial results and provide a general business update on Wednesday, August 5, 2009, at 4:30 p.m. Eastern Time. A press release ...